Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Novartis

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Novartis' 2013 sales performance.

Novartis

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

If approved (possibly in 2023) it would be a competitor to Novartis’ and Gilead/Kite’s CART-T therapies – Kymriah and Yescarta, respectively – which also target CD19 receptors.

ZPB Associates acquires PR specialist Journalista

ZPB Associates acquires PR specialist Journalista This includes Novartis, Amazon Web Services and Push Doctor. “ZPB and Journalista operate in similar spaces, with shared values, mutually supportive services and a vision for making complex issues clearer for

Novartis makes case for NASH candidate tropifexor

Novartis makes case for NASH candidate tropifexor Race to market intensifies as rivals strive to win first-in-class. Novartis has announced positive data for its NASH candidate tropifexor, building the case for the drug as it races

Sandoz expands into Japan with €400m Aspen deal

Sandoz expands into Japan with €400m Aspen deal Sandoz, the generics division of Swiss pharma Novartis, has agreed to acquire South Africa-based Aspen’s Japanese operations and associated assets to bolster its global presence. . ... Japan’s generic medicines market is the third largest globally,

Roche’s Spinraza, Zolgensma rival risdiplam hits the mark in SMA

Roche’s Spinraza, Zolgensma rival risdiplam hits the mark in SMA If it does get a green light, risdiplam would compete in the market with Biogen’s blockbuster antisense-based SMA medicine  Spinraza (nusinersen) as well as Novartis’ recently-approved gene therapy  ... Spinraza’s third-quarter showed a dip in

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics